Odyssey
  • Homepage
  • Objectives
  • News
  • Publications
  • Privacy
    • Privacy Policy
    • Cookie Policy
  • Contact
  • Restricted
Select Page

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

by Communication Team | Aug 6, 2020 | Publication

Authors: Bollen PDJ, Moore C, Mujuru H, et al. The ODYSSEY Trial Team
Published in: LANCET HIV. 2020;8:e533-e544


Download

Recent Posts

  • ‘Because we all have to grow up;’ supporting adolescents to develop core competencies to transition towards managing their HIV independently
  • ODYSSEY team at Radboud receives the RIHS Societal Award 2020
  • DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI- BASED ART IN CHILDREN AND ADOLESCENTS
  • ODYSSEY trial finds new drug is better for treating children living with HIV
  • ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

Recent Comments

    Archives

    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • August 2020
    • June 2020
    • May 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • August 2019
    • July 2019
    • March 2019
    • July 2018
    • June 2018
    • April 2018
    • August 2017
    • September 2016

    Categories

    • ODYSSEY
    • Publication

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    This study is funded by ViiV Healthcare and the sponsor is Penta Foundation